

# Mayumi Sugita

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1682144/publications.pdf>

Version: 2024-02-01

14  
papers

768  
citations

1040056

9  
h-index

1199594

12  
g-index

14  
all docs

14  
docs citations

14  
times ranked

1673  
citing authors

#	ARTICLE	IF	CITATIONS
1	Methods to monitor in vivo expansion and efficacy of CAR-T cells in preclinical models. <i>Methods in Cell Biology</i> , 2022, 167, 185-201.	1.1	0
2	Allogeneic TCR $\beta$ <sup>-/-</sup> deficient CAR T-cells targeting CD123 in acute myeloid leukemia. <i>Nature Communications</i> , 2022, 13, 2227.	12.8	25
3	Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells. <i>Nature Communications</i> , 2022, 13, 2228.	12.8	14
4	BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells. <i>Blood</i> , 2021, 137, 812-825.	1.4	18
5	Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia. <i>Npj Precision Oncology</i> , 2021, 5, 44.	5.4	20
6	CD123 as a Therapeutic Target Against Malignant Stem Cells. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 553-564.	2.2	18
7	Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting. <i>British Journal of Haematology</i> , 2020, 190, 891-900.	2.5	11
8	Chemical probes and methods for single-cell detection and quantification of epichaperomes in hematologic malignancies. <i>Methods in Enzymology</i> , 2020, 639, 289-311.	1.0	9
9	Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia. <i>Blood Advances</i> , 2019, 3, 1061-1072.	5.2	42
10	Efficacy Proof of Concept for Allogeneic CD123 Targeting CAR T-Cells Against Primary Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Efficient Control of Tumor Progression in PDX Model and Potential Loss of CD123 Expression in Relapsed Disease. <i>Blood</i> , 2019, 134, 2659-2659.	1.4	0
11	Selection and characterization of antibody clones are critical for accurate flow cytometry-based monitoring of CD123 in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 978-982.	1.3	11
12	Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism. <i>Cancer Discovery</i> , 2017, 7, 716-735.	9.4	582
13	Allogeneic Tcr $\beta$ <sup>-/-</sup> Deficient CAR T-Cells Targeting CD123 Prolong Overall Survival of AML Patient-Derived Xenografts. <i>Blood</i> , 2016, 128, 765-765.	1.4	16
14	In Vivo Response to Cytarabine Chemotherapy Uncovers the Role of the Oxidative and Energetic Metabolism in the Chemoresistance of Human Primary AML Stem Cells. <i>Blood</i> , 2015, 126, 4269-4269.	1.4	2